

Naveen Pemmaraju

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3195177/publications.pdf>

Version: 2024-02-01

230
papers

8,334
citations

57758

44
h-index

66911

78
g-index

233
all docs

233
docs citations

233
times ranked

7961
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	27.0	388
2	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019, 9, 370-383.	9.4	380
3	Clinical experience with the BCL2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 401-407.	4.1	336
4	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. <i>New England Journal of Medicine</i> , 2019, 380, 1628-1637.	27.0	274
5	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , 2019, 12, 1.	17.0	257
6	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i> , 2018, 132, 2115-2124.	1.4	232
7	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology</i> , 2015, 2, e186-e193.	4.6	227
8	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e724-e736.	4.6	201
9	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. <i>Blood</i> , 2014, 124, 385-392.	1.4	195
10	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e618-e627.	4.6	190
11	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	1.6	173
12	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. <i>Cancer Discovery</i> , 2017, 7, 156-164.	9.4	164
13	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	1.6	156
14	TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. <i>American Journal of Hematology</i> , 2013, 88, 1055-1061.	4.1	120
15	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	5.2	106
16	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 313-319.	27.6	103
17	Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). <i>Cancer</i> , 2014, 120, 3660-3668.	4.1	91
18	Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 449-455.	2.3	91

#	ARTICLE	IF	CITATIONS
19	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	5.2	86
20	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e552-e561.	4.6	81
21	Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders. <i>Haematologica</i> , 2010, 95, 1090-1097.	3.5	79
22	Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2018, 124, 2758-2765.	4.1	78
23	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. <i>Leukemia</i> , 2017, 31, 678-687.	7.2	77
24	Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2012, 97, 1029-1035.	3.5	74
25	HyperCVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	4.1	74
26	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. <i>Leukemia Research</i> , 2015, 39, 950-956.	0.8	69
27	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	4.6	66
28	Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. <i>British Journal of Haematology</i> , 2015, 168, 646-653.	2.5	64
29	Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. <i>Leukemia Research</i> , 2018, 73, 21-23.	0.8	62
30	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. <i>Blood</i> , 2018, 132, 1664-1674.	1.4	62
31	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. <i>Journal of Clinical Oncology</i> , 2022, 40, 1671-1680.	1.6	60
32	Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1429-1437.	3.7	59
33	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	4.1	59
34	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 47-53.	2.0	58
35	Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends. <i>Journal of Oncology Practice</i> , 2017, 13, e623-e631.	2.5	58
36	Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. <i>Blood Cancer Journal</i> , 2019, 9, 4.	6.2	57

#	ARTICLE	IF	CITATIONS
37	Treating Leukemia in the Time of COVID-19. <i>Acta Haematologica</i> , 2021, 144, 132-145.	1.4	57
38	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	5.2	56
39	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018, 93, 277-285.	4.1	54
40	Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. <i>Leukemia Research</i> , 2017, 59, 110-116.	0.8	53
41	A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. <i>Scientific Reports</i> , 2017, 7, 11253.	3.3	52
42	Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. <i>Blood</i> , 2013, 122, 2807-2811.	1.4	50
43	Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 358-363.	0.4	50
44	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	5.0	50
45	Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. <i>Blood Advances</i> , 2020, 4, 4020-4027.	5.2	48
46	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≥ 60 years with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 961-966.	4.1	46
47	Identification of a Novel Fusion Gene, IRF2BP2-RARA, in Acute Promyelocytic Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 19-22.	4.9	46
48	Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. <i>Cancer Discovery</i> , 2022, 12, 522-541.	9.4	44
49	Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. <i>Blood</i> , 2019, 133, 2348-2351.	1.4	43
50	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	4.6	43
51	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacytidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	1.6	41
52	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2018, 93, 84-90.	4.1	40
53	Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. <i>European Journal of Haematology</i> , 2018, 100, 257-263.	2.2	40
54	Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , 2021, 106, 1047-1055.	3.5	40

#	ARTICLE	IF	CITATIONS
55	Outcomes in patients with newly diagnosed <i>TP53</i> -mutated acute myeloid leukemia with or without venetoclax-based therapy. <i>Cancer</i> , 2021, 127, 3541-3551.	4.1	40
56	Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2019, 134, 734-734.	1.4	40
57	The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette. <i>Seminars in Hematology</i> , 2017, 54, 184-188.	3.4	39
58	Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. <i>American Journal of Hematology</i> , 2015, 90, 27-30.	4.1	38
59	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017, 92, 599-606.	4.1	38
60	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4430-4439.	4.1	37
61	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492.	7.2	37
62	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 845-850.	4.1	36
63	Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 110-114.	0.4	35
64	Erythroleukemia-historical perspectives and recent advances in diagnosis and management. <i>Blood Reviews</i> , 2018, 32, 96-105.	5.7	35
65	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. <i>Blood Advances</i> , 2018, 2, 1807-1816.	5.2	34
66	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2021, 106, 2121-2130.	3.5	34
67	A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771.	4.1	34
68	Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. <i>Blood Advances</i> , 2021, 5, 2156-2164.	5.2	33
69	Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864.	4.1	33
70	Hypomethylating agent and venetoclax with FLT3 inhibitor cetrinplet therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	6.2	33
71	Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. <i>American Journal of Hematology</i> , 2017, 92, 279-285.	4.1	32
72	The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2018, 97, 2071-2080.	1.8	32

#	ARTICLE	IF	CITATIONS
73	Prognostic significance of baseline <i>FLT3</i> mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991.	4.1	32
74	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood, 2021, 138, 1373-1377.	1.4	31
75	Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, 1035-1043.	4.1	31
76	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leukemia Research, 2014, 38, 1126-1129.	0.8	29
77	Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond. Current Hematologic Malignancy Reports, 2017, 12, 510-512.	2.3	29
78	8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. Leukemia Research, 2018, 66, 73-78.	0.8	29
79	SMAC mimetics as potential cancer therapeutics in myeloid malignancies. British Journal of Haematology, 2019, 185, 219-231.	2.5	29
80	Mutated <i>NPM1</i> in patients with acute myeloid leukemia in remission and relapse. Leukemia and Lymphoma, 2014, 55, 1337-1344.	1.3	28
81	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1288-1295.	4.1	28
82	Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Annals of Hematology, 2018, 97, 109-121.	1.8	27
83	Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. American Journal of Hematology, 2015, 90, 1091-1092.	4.1	26
84	Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 213-222.e2.	0.4	26
85	Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer Journal, 2019, 9, 99.	6.2	26
86	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematology, 2022, 9, e350-e360.	4.6	26
87	Outcomes in Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Treated With or Without Autologous or Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 485-492.	0.4	25
88	Topoisomerase II inhibitors in AML: past, present, and future. Expert Opinion on Pharmacotherapy, 2019, 20, 1637-1644.	1.8	25
89	Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood, 2019, 134, 4163-4163.	1.4	25
90	An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. American Journal of Hematology, 2017, 92, 674-682.	4.1	24

#	ARTICLE	IF	CITATIONS
91	Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, 543-545.	2.5	24
92	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. <i>Blood Cancer Journal</i> , 2021, 11, 98.	6.2	24
93	Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. <i>Cancer</i> , 2021, 127, 4213-4220.	4.1	24
94	Disease-specific hashtags and the creation of Twitter medical communities in hematology and oncology. <i>Seminars in Hematology</i> , 2017, 54, 189-192.	3.4	24
95	Defining disease modification in myelofibrosis in the era of targeted therapy. <i>Cancer</i> , 2022, 128, 2420-2432.	4.1	24
96	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1000-1007.	4.1	23
97	Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 734-740.	0.4	23
98	Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. <i>Leukemia</i> , 2022, 36, 1343-1350.	7.2	23
99	Social Media and Myeloproliferative Neoplasms (MPN) – Focus on Twitter and the Development of a Disease-specific Community: #MPNSM. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 413-420.	2.3	22
100	Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media – #MPNSM. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 598-604.	2.3	22
101	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	7.2	22
102	The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2020, 136, 49-50.	1.4	21
103	Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. <i>Blood</i> , 2021, 138, 2346-2346.	1.4	21
104	Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature. <i>Acta Haematologica</i> , 2014, 132, 298-306.	1.4	19
105	Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 456-461.	2.3	19
106	Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 941-946.	3.1	19
107	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. <i>Cancer</i> , 2020, 126, 4322-4331.	4.1	19
108	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1733-1739.	1.4	19

#	ARTICLE	IF	CITATIONS
109	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2019, 134, 558-558.	1.4	19
110	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Bone Marrow Transplantation</i> , 2022, 57, 51-56.	2.4	19
111	Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Journal of Clinical Oncology</i> , 2022, 40, 3032-3036.	1.6	19
112	Glioblastoma and acute myeloid leukemia: malignancies with striking similarities. <i>Journal of Neuro-Oncology</i> , 2018, 136, 223-231.	2.9	18
113	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. <i>Journal of Hematology and Oncology</i> , 2020, 13, 132.	17.0	18
114	Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. <i>Leukemia</i> , 2021, 35, 3299-3303.	7.2	18
115	Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2016, 128, 4039-4039.	1.4	18
116	Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. <i>Lancet Haematology</i> , 2022, 9, e434-e444.	4.6	18
117	Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. <i>Blood Advances</i> , 2021, 5, 3163-3173.	5.2	17
118	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. <i>American Journal of Hematology</i> , 2022, 97, E62.	4.1	17
119	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. <i>Blood Advances</i> , 2022, 6, 3027-3035.	5.2	17
120	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 813-820.	1.3	16
121	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 1494-1499.	7.2	16
122	Clinical Profile of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2020, 136, 11-13.	1.4	16
123	Improved survival of patients with myelofibrosis in the last decade: Single-center experience. <i>Cancer</i> , 2022, , .	4.1	16
124	Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2021, 62, 528-537.	1.3	15
125	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. <i>Blood</i> , 2019, 134, 2637-2637.	1.4	15
126	Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3795-3795.	1.4	15

#	ARTICLE	IF	CITATIONS
127	Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). <i>Blood</i> , 2016, 128, 3105-3105.	1.4	15
128	Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2021, 13, 5888.	3.7	15
129	Improved outcomes among newly diagnosed patients with <sc>FMSâ€like tyrosine kinase 3 internal tandem duplication</sc> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. <i>American Journal of Hematology</i> , 2022, 97, 329-337.	4.1	15
130	Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. <i>Leukemia Research</i> , 2022, 115, 106809.	0.8	15
131	Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 462-467.	2.3	14
132	Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 460-468.	2.3	14
133	Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071987473.	2.5	14
134	Leveraging Social Media for Cardio-Oncology. <i>Current Treatment Options in Oncology</i> , 2020, 21, 83.	3.0	14
135	LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. <i>Blood</i> , 2018, 132, 687-687.	1.4	14
136	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. <i>Blood</i> , 2019, 134, 2723-2723.	1.4	14
137	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. <i>Nature Communications</i> , 2022, 13, 2228.	12.8	14
138	Clinical outcomes in adult patients with aplastic anemia: A single institution experience. <i>American Journal of Hematology</i> , 2017, 92, 1295-1302.	4.1	13
139	Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Haematologica</i> , 2017, 102, 1709-1717.	3.5	13
140	Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 592-597.	2.3	13
141	Early detection of transformation to BPDCN in a patient with MDS. <i>Experimental Hematology and Oncology</i> , 2018, 7, 26.	5.0	13
142	Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 914-924.	4.1	13
143	Disseminated <i><sc>S</sc>aprochaete capitata</i> (formerly known as <i><sc>G</sc>eotrichum) Tj ETQq1 1 0.784314 rgBT /Ov leukemia. <i>European Journal of Haematology</i> , 2014, 93, 543-544.	2.2	12
144	PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2019, 11, 695.	3.7	12

#	ARTICLE	IF	CITATIONS
145	Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematology/Oncology Clinics of North America, 2020, 34, 565-574.	2.2	12
146	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). Blood, 2018, 132, 1821-1821.	1.4	12
147	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 2161-2170.	1.3	12
148	Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 318-327.e6.	0.4	11
149	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood, 2020, 136, 42-43.	1.4	11
150	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes. Blood, 2015, 126, 3746-3746.	1.4	11
151	Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing.. Journal of Clinical Oncology, 2016, 34, 7006-7006.	1.6	11
152	A Single Case of Rosai-Dorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine. Frontiers in Oncology, 2014, 4, 297.	2.8	10
153	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN "Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. Current Hematologic Malignancy Reports, 2018, 13, 581-587.	2.3	10
154	Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Current Hematologic Malignancy Reports, 2019, 14, 515-522.	2.3	10
155	Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opinion on Biological Therapy, 2020, 20, 115-123.	3.1	10
156	Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Expert Review of Anticancer Therapy, 2020, 20, 543-550.	2.4	10
157	Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. Leukemia and Lymphoma, 2021, 62, 2568-2586.	1.3	10
158	Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood, 2018, 132, 4057-4057.	1.4	10
159	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. Blood, 2020, 136, 39-40.	1.4	10
160	Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN).. Journal of Clinical Oncology, 2012, 30, 6578-6578.	1.6	10
161	Social Media for Hematopathologists: Medical Practice Reinvented " #Hemepath. Current Hematologic Malignancy Reports, 2020, 15, 383-390.	2.3	9
162	Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. American Journal of Hematology, 2020, 95, E225-E228.	4.1	9

#	ARTICLE	IF	CITATIONS
163	Targeting the p-D-C: easy as C-D-1-2-3?. Blood, 2021, 137, 1277-1278.	1.4	9
164	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<sc>MDS/MPN</sc>) and myelodysplastic syndrome with ring sideroblasts (<sc>MDS</sc>). American Journal of Hematology, 2021, 96, E246-E249.	4.1	9
165	SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 210-223.	0.4	9
166	Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2022, 97, 574-582.	4.1	9
167	Blastic plasmacytoid dendritic cell neoplasm (<sc>BPDCN</sc>): A promising future in the era of targeted therapeutics. Cancer, 2022, 128, 3019-3026.	4.1	9
168	Disseminated histoplasmosis as pseudo <sc>R</sc>icter's transformation in a patient with chronic lymphocytic leukemia. American Journal of Hematology, 2015, 90, 752-753.	4.1	8
169	<sc>PET</sc>-positive lymphadenopathy in <sc>CLL</sc>—Not always <sc>R</sc>icter transformation. American Journal of Hematology, 2017, 92, 405-406.	4.1	8
170	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E50-E53.	4.1	8
171	The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond. Current Hematologic Malignancy Reports, 2021, 16, 132-139.	2.3	8
172	Targeting CD123 in BPDCN: an emerging field. Expert Review of Hematology, 2021, 14, 993-1004.	2.2	8
173	Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): The MD Anderson Cancer Center (MDACC) Experience. Blood, 2008, 112, 3982-3982.	1.4	8
174	Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies. Clinical Hematology International, 2019, 1, 2.	1.7	8
175	Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2022, 14, 3375.	3.7	8
176	Editorial overview: Emerging importance of social media for real-time communication in the modern medical era. Seminars in Hematology, 2017, 54, 175-176.	3.4	7
177	Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing) Tj ETQq1 1 0.784314 rgBJ /Overl Myeloid Leukemia. Blood, 2020, 136, 41-42.	1.4	7
178	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2013, 122, 2682-2682.	1.4	7
179	From Philadelphia-Negative to <i>JAK2</i>-Positive: Effect of Genetic Discovery on Risk Stratification and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 139-145.	3.8	6
180	Acute promyelocytic leukemia (APL) with an <i>IRF2BP2-RARA</i> fusion transcript: an aggressive APL variant. Leukemia and Lymphoma, 2020, 61, 3018-3020.	1.3	6

#	ARTICLE	IF	CITATIONS
181	Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 491-499.	2.4	6
182	CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2021, , 1-12.	1.3	6
183	Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7058-7058.	1.6	6
184	CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2022, 14, 2287.	3.7	6
185	Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era. <i>Leukemia and Lymphoma</i> , 2021, 62, 2253-2260.	1.3	5
186	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. <i>Cancer</i> , 2021, 127, 3113-3124.	4.1	5
187	Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. <i>Blood</i> , 2019, 134, 1656-1656.	1.4	5
188	Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms. <i>EJHaem</i> , 2022, 3, 954-957.	1.0	5
189	Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 102.	0.8	4
190	Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. <i>European Journal of Haematology</i> , 2013, 91, n/a-n/a.	2.2	4
191	Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. <i>Leukemia and Lymphoma</i> , 2017, 58, 866-871.	1.3	4
192	Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2775-2777.	1.3	4
193	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline <i>RUNX1</i> mutations. <i>American Journal of Hematology</i> , 2020, 95, E313-E315.	4.1	4
194	Clinical value of event-free survival in acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1690-1699.	5.2	4
195	Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Models. <i>Blood</i> , 2018, 132, 3956-3956.	1.4	4
196	Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis. <i>Blood</i> , 2019, 134, 4178-4178.	1.4	4
197	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	4.1	4
198	Solifenacin-induced small bowel pseudo-obstruction. <i>Journal of Hospital Medicine</i> , 2008, 3, 176-178.	1.4	3

#	ARTICLE	IF	CITATIONS
199	Successful treatment of aplastic anemiaâ€“paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 765-767.	0.5	3
200	<i>DNMT3A</i>, <i>TET2</i>, and <i>JAK2</i> mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1969-1973.	1.3	3
201	<i>Plesiomonas shigelloides</i> gastroenteritis in a patient with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3341-3342.	1.3	3
202	lluminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. <i>Hematological Oncology</i> , 2020, 38, 654-664.	1.7	3
203	Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 409-429.	2.2	3
204	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2018, 132, 1773-1773.	1.4	3
205	Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 1391-1391.	1.4	3
206	Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7118-7118.	1.6	3
207	Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-XI Inhibitor Pelcitolax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy. <i>Blood</i> , 2020, 136, 15-16.	1.4	3
208	Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 431-438.	1.8	3
209	Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML. <i>American Journal of Hematology</i> , 2017, 92, 119-120.	4.1	2
210	Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E357-E360.	4.1	2
211	Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, e10-e13.	2.5	2
212	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). <i>American Journal of Hematology</i> , 2020, 95, E326-E329.	4.1	2
213	Treating Rosaiâ€“Dorfman disease and RASâ€“associated autoimmune leucoproliferative disorder with malignant transformation. <i>British Journal of Haematology</i> , 2021, 192, 667-671.	2.5	2
214	#JACCCardioOnc. <i>JACC: CardioOncology</i> , 2021, 3, 461-464.	4.0	2
215	Questions on asparaginase-associated pancreatitis. <i>Lancet Oncology, The</i> , 2017, 18, 1148-1149.	10.7	2
216	Phase 2 Study of Tagraxofusp Therapy for BPDCN Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 5-5.	1.4	2

#	ARTICLE	IF	CITATIONS
217	How to Treat Adult Acute Myeloid Leukemia. <i>JACC: CardioOncology</i> , 2021, 3, 747-751.	4.0	2
218	Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020, 98, 106445.	0.8	1
219	AML-373: Tagraxofusp, a CD123-Targeted Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Results of a Landmark Clinical Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S209-S210.	0.4	1
220	MPN-379: Interim Results from an Ongoing Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Chronic Myelomonocytic Leukemia (CMML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S339.	0.4	1
221	Chronic Myelomonocytic Leukemia: Hematopathology Perspective. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 142-149.	1.4	1
222	Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis. <i>Blood</i> , 2020, 136, 13-14.	1.4	1
223	Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients. <i>Blood</i> , 2020, 136, 1-3.	1.4	1
224	Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. <i>Blood Advances</i> , 2022, 6, 5546-5549.	5.2	1
225	Major Clinical Response in a Patient with Leukemia Cutis Treated with the Bromodomain Inhibitor PLX51107 and Azacitidine. <i>Leukemia Research</i> , 2022, 119, 106884.	0.8	1
226	The Sacred Trust. <i>American Journal of Kidney Diseases</i> , 2015, 66, A17-A19.	1.9	0
227	Healing words. <i>Cmaj</i> , 2015, 187, 360-361.	2.0	0
228	Patient with mixed-phenotype acute leukemia with CFBF rearrangement. <i>Leukemia and Lymphoma</i> , 2019, 60, 2829-2831.	1.3	0
229	A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic. <i>Cancer</i> , 2021, 127, 2867-2869.	4.1	0
230	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. <i>Modern Pathology</i> , 0, , .	5.5	0